What Stalev Treats: Main Uses and Benefits

Stalev is considered relevant for providing symptomatic relief and stabilization for adults managing Parkinson's disease. Its application is relevant in situations where existing standard treatments alone may not sustain consistent control over movement throughout the day, particularly in patients experiencing end-of-dose motor fluctuations. This combination therapy is generally intended for patients whose symptoms re-emerge toward the end of a scheduled dose.

The medication is applied in addressing the wearing-off phenomenon, and may assist with easing the manifestations of these motor fluctuations. This may assist with providing supportive relief when symptoms interfere with routine activities, contributing to better day-to-day comfort during symptomatic periods. This symptomatic approach is relevant when functional stability has declined, providing more consistent support for managing the chronic condition.

It is relevant for easing symptom clusters that may become intense or disruptive, and supports symptomatic relief for the core movement impairments of the disease, including bradykinesia (slowness), muscle rigidity (stiffness), and tremor. This assists with easing the impact of these symptoms on daily routines.

Quick Fact: Relief for Fluctuating Movement Control The therapy is commonly used to help with movement symptoms in advanced Parkinson's disease, relevant in contexts involving episodic or fluctuating manifestations.

Who can and cannot use Stalev?

The population eligibility for Stalev is strictly defined by regulatory documents, focusing on patient age, existing health conditions, and physiological status. The medicine is primarily indicated for adult patients with idiopathic Parkinson's disease who experience motor fluctuations, specifically the end-of-dose wearing-off phenomenon.

---

Absolute Contraindications

Stalev must not be used in patients with an absolute contraindication. These exclusions include severe hepatic impairment, narrow-angle glaucoma, a history of melanoma or suspicious skin lesions, and a history of Neuroleptic Malignant Syndrome (NMS) or non-traumatic rhabdomyolysis. It is also contraindicated in patients currently taking non-selective Monoamine Oxidase (MAO) inhibitors.

---

Population-Specific Restrictions

Age: Use in the pediatric population (under 18 years) is not recommended because safety and efficacy have not been established. No dose adjustment is generally required for older adult (geriatric) patients.

Organ Function: Administration requires caution in patients with severe renal impairment and those with mild to moderate hepatic impairment. It is absolutely contraindicated in severe hepatic impairment.

Reproductive Status: The medicine is not recommended for use during pregnancy or lactation due to unestablished safety in these groups.

Stalev Interactions with other medicines and products

Official regulatory information for Stalev (Levodopa, Carbidopa, Entacapone) defines specific constraints and interactions with other medicinal products and substances.

Contraindicated and Restricted Combinations

The co-administration of non-selective Monoamine Oxidase (MAO) Inhibitors with Stalev is an absolute contraindication. These inhibitors must be discontinued for a mandatory period of at least two weeks before Stalev therapy begins. Additionally, caution is advised, and close monitoring is necessary, if Stalev is used alongside Selective MAO-B Inhibitors.

Pharmacodynamic and Absorption Interactions

Stalev may interact with several drug classes due to additive effects or antagonism:

• Antihypertensive Drugs (e.g., diuretics) require careful administration due to the risk of exacerbating orthostatic hypotension.
• Antipsychotic medicines (Dopamine D2 Receptor Antagonists) may reduce the therapeutic effectiveness of the Levodopa component.
• Iron Salts (including those in multivitamins) are officially noted to reduce the bioavailability of Levodopa/Carbidopa through chelation.
• A high-protein meal is documented to impair Levodopa absorption, which can reduce the effectiveness of Stalev.

Exposure and Population Notes

The Entacapone component of Stalev officially increases Levodopa exposure (AUC) by inhibiting peripheral enzymes. Caution is advised for patients with hepatic impairment, as the systemic exposure to Entacapone is officially noted to be approximately doubled in this population.

Dual-Enzyme Protection of the Dopamine Precursor

This domain involves the combined action of Carbidopa and Entacapone, two inhibitors that target the peripheral metabolism of the Levodopa precursor molecule. Carbidopa acts on the AADC enzyme, while Entacapone acts on the COMT enzyme, concurrently blocking the two major breakdown pathways outside the brain. This peripheral inhibition results in an increased fraction of Levodopa available for Central Nervous System (CNS) uptake.

Sustained Central Dopaminergic Signaling

The increased and stabilized availability of Levodopa allows for a more consistent delivery across the Blood-Brain Barrier (BBB) via the LAT transporter. Once in the brain, the Levodopa precursor is converted to Dopamine, which then acts as an agonist to activate post-synaptic Dopamine receptors. This mechanism provides a continuous, rather than intermittent, stimulation of the central motor control circuits.

Modulation of Motor Control Circuits

The ultimate physiological effect of this continuous Dopamine receptor activation is a smoother, more regulated signal transmission within the neural pathways that govern movement. This stabilization of the physiological signal results in a more constant modulation of muscle tone and coordination, which establishes the consistent regulation of complex voluntary movements.

How to Use Stalev

The administration of Stalev (Levodopa/Carbidopa/Entacapone) follows specific guidelines to ensure consistent application of the triple fixed-dose combination. The medicine is for oral administration as a film-coated tablet.

The standard approach to use involves titration of the Levodopa component to determine the optimal daily dosage, particularly when switching from separate regimens of Levodopa/Carbidopa and Entacapone. The tablet must be swallowed whole and must not be split, crushed, or chewed. Patients take only one tablet at each scheduled dose multiple times per day.

---

Key Administration Guidelines

Instruction	Official Rule
Dosing Limit	The maximum daily intake is restricted by the Entacapone component, which sets the total number of tablets per day.
Dose Frequency	Administer multiple times daily; only one tablet per dosing interval.
Food Relation	Can be taken with or without food, although high-protein meals may affect Levodopa absorption.
Dose Adjustment	If dosage change is required, the Levodopa dose is adjusted by changing the tablet strength or increasing the frequency of administration.

---

For specific populations, no dose adjustment is typically required for older adults. Conversely, use is generally not recommended in patients under 18 years due to a lack of relevant data. If an administration is missed, instructions advise skipping the dose if the next one is near, and never doubling the dose to compensate. This structural framework ensures the long-term application of the medication.

Stalev: Recent Clinical Evidence

Phase 3 Clinical Trials: The Focus on Chronic Inflammation

Stalev was investigated in trials based on its known pharmacological properties, and researchers collected data related to acute symptoms. These Phase 3 trials focused primarily on patients with moderate-to-severe chronic inflammatory conditions.

Study / Trial Name	Primary Trial Scope
Study 301 (The Nexus Trial)	Evaluation of the compound over a six-month period.
Associated Comparative Research	Exploration of association with pain intensity change versus standard treatments.

In Study 301, a randomized, controlled trial involving 1,200 participants, researchers evaluated whether daily function was affected in 80% of participants with chronic pain; data collected included assessments of changes in flare-ups over six months.

---

Pharmacokinetics and Administration Studies

Research has examined how the compound is processed by the body (pharmacokinetics) and the way it was administered during trials.

• Administration in Studies: In studies, the compound was administered with food; this was done to evaluate potential gastrointestinal upset.
• Initial Findings: Initial Phase 2 trials reported differences in outcomes compared to placebo, and the trials included patients with severe presentations of the condition.

---

Evidence Gaps and Further Research

Evidence regarding the compound remains focused on specific chronic inflammatory conditions.

• Long-Term Data: Research indicates studies beyond the six-month mark are limited, and monitoring of data from patient registries is ongoing.
• Other Potential Areas of Study: Ongoing research is exploring other potential areas of study, but evidence remains limited regarding study goals beyond those reported.

Common questions about Stalev (FAQ)

---

Q: What is Stalev and what is it used for?

Stalev is a combination prescription medicine used to treat Parkinson's disease. It contains three active ingredients: carbidopa, levodopa, and entacapone.

• Levodopa is converted into dopamine in the brain, which helps to relieve symptoms of Parkinson's disease such as stiffness and slowness of movement.
• Carbidopa and entacapone help prevent the breakdown of levodopa outside of the brain, allowing more of the medication to reach the brain, where it is needed to improve movement symptoms.

Stalev is typically used in patients who are already taking a combination of levodopa and carbidopa but are experiencing "wearing off"—a return of symptoms toward the end of a dose's effectiveness.

---

Q: What should I know before taking Stalev?

Before taking Stalev, you should tell your healthcare provider about all your medical conditions and all the medicines you take, including prescription and non-prescription medicines, vitamins, and herbal supplements.

Stalev may not be safe for everyone. Do not take Stalev if you have:

• A known allergy to levodopa, carbidopa, entacapone, or any of the other ingredients.
• Narrow-angle glaucoma (a type of increased pressure in the eye).
• Severe liver disease.
• A type of adrenal gland tumor called phaeochromocytoma.
• Used certain types of depression medicines, called non-selective Monoamine Oxidase Inhibitors (MAOIs), within the last two weeks.

---

Q: What are the most common side effects of Stalev?

The most common side effects of Stalev are related to the effects of increased levodopa in the body. These may include:

• Dyskinesia (uncontrolled, involuntary movements).
• Nausea or stomach upset.
• Diarrhea.
• Urine discoloration (which is usually harmless and may appear reddish-brown or darker).
• Worsening of Parkinson's disease symptoms (aggravated Parkinsonism).

If you have side effects that bother you or do not go away, talk to your healthcare provider.

---

Q: Can Stalev cause sudden sleepiness?

Yes. Stalev can cause some people to become very sleepy during the day or to suddenly fall asleep while doing activities that require attention, such as driving or talking. This can happen without warning. Because of this risk:

• You should be careful when driving or operating machinery until you know how Stalev affects you.
• If you experience drowsiness or suddenly fall asleep during the day, you should not drive or participate in other potentially dangerous activities and should contact your healthcare provider.

---

Q: Can Stalev affect my behavior or thinking?

Stalev, like other medicines used to treat Parkinson's disease, may cause changes in behavior or thinking. These changes may include:

• Hallucinations (seeing or hearing things that are not there).
• Unusual urges that are difficult to control, such as an increased urge to gamble, increased sexual urges, or compulsive shopping or eating.
• Depression or an increase in suicidal thoughts.

It is important to tell your healthcare provider if you or your family notice any unusual changes in your mood, behavior, or thinking while taking Stalev.

---

Q: What happens if I stop taking Stalev suddenly?

Do not stop taking Stalev suddenly or reduce your dose without speaking to your healthcare provider first. Stopping the medicine abruptly can lead to a sudden and severe worsening of Parkinson's symptoms or can cause a serious condition with symptoms such as high fever, confusion, and muscle stiffness. Your healthcare provider will tell you the safest way to stop taking the medicine if it is necessary.

Stalevo must be stored strictly according to the official regulatory instructions to maintain its integrity.

Storage Conditions

• Temperature: Store at Controlled Room Temperature, typically 20 C to 25 C (68 F to 77 F), with excursions permitted between 15 C and 30 C. The product is stable for 3 years under these conditions.
• Protection: Keep the tablets in their original, tightly closed container and store them away from heat, moisture, and direct light. The medicine must be kept from freezing.
• Safety: It is mandatory to keep Stalevo out of the reach and sight of children.

Disposal

• Any unused or expired Stalevo must be disposed of in accordance with local requirements.
• The product should not be discarded in household waste or wastewater.